Results 71 to 80 of about 2,751,693 (208)

Suppression of STAT5A increases chemotherapeutic sensitivity in imatinib-resistant and imatinib-sensitive K562 cells [PDF]

open access: yesLeukemia & Lymphoma, 2010
STAT proteins are cytoplasmic transcription factors that are involved in the regulation of numerous cellular activities such as cell growth, differentiation, and survival. In this study, we aimed to identify the expression pattern of STAT genes in imatinib-sensitive and -resistant K562 cells, and further, to reveal the effects of STAT5A siRNA knockdown
Kosova, Buket   +8 more
openaire   +3 more sources

Whole‐genome and transcriptome analysis in relapsed/refractory non‐Hodgkin lymphoma: Results from a multicentre precision oncology cohort

open access: yesBritish Journal of Haematology, EarlyView.
Summary Comprehensive genome and transcriptome profiling can inform the diagnosis, prognosis and management of relapsed/refractory (R/R) solid malignancies, yet its integration into clinical care has lagged despite strong biological rationale. We evaluated the clinical utility of whole genome and transcriptome analysis (WGTA) in 65 patients (37 ...
Kathleen Wee   +24 more
wiley   +1 more source

Nilotinib concentration in cell lines and primary CD34+ chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters [PDF]

open access: yes, 2009
Imatinib mesylate and nilotinib are highly effective at eradicating the majority of chronic myeloid leukemia (CML) cells; however, neither agent induces apoptosis of primitive CML CD34<sup>+</sup> cells.
Holyoake, T.L.   +10 more
core   +2 more sources

Development and targeted use of nilotinib in chronic myeloid leukemia

open access: yesDrug Design, Development and Therapy, 2008
Carmen Fava, Hagop Kantarjian, Jorge Cortes, Elias JabbourDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USAAbstract: The development of imatinib has resulted in sustained hematologic and cytogenetic remissions
Carmen Fava   +3 more
doaj  

Imatinib mesylate resistance and mutations: An Indian experience

open access: yesIndian Journal of Medical and Paediatric Oncology, 2013
AbstractThe treatment of chronic myeloid leukemia (CML) has been revolutionized by the small molecule selective kinase inhibitor imatinib mesylate. Imanitib was the first BCR-ABL targeted agent approved for the treatment of CML patients and confers significant response in most patients; however, a substantial number of patients are initially refractory
Shweta Srivastava, Sarjana Dutt
openaire   +3 more sources

New anti‐inflammatory and remodelling drugs for unmet clinical needs in severe asthma and chronic obstructive pulmonary disease (COPD)

open access: yesBritish Journal of Pharmacology, EarlyView.
There have been several step‐changes in asthma therapy, with the first being the use of inhaled short‐acting β2‐agonists as bronchodilators and the introduction of inhaled corticosteroids (ICS) to reduce airway inflammation. The next revolution was the advent of inhaled combinations of long‐acting bronchodilators together with inhaled corticosteroids ...
Ian M. Adcock
wiley   +1 more source

Bcr-Abl mutations, resistance to imatinib, and imatinib plasma levels

open access: yesBlood, 2003
Corbin and colleagues analyze in their report[1][1] the biochemical and biologic effects of several mutations in the kinase domain of the Bcr-Abl protein identified in patients who developed resistance to imatinib.
GAMBACORTI PASSERINI, CARLO   +2 more
openaire   +2 more sources

Treatment‐Free Remission in Chronic Myeloid Leukemia: Toward Precision and Personalized Approaches to Functional Cure

open access: yesCancer Science, EarlyView.
Immune surveillance of residual leukemic stem cells after tyrosine kinase inhibitor discontinuation involves coordinated NK‐cell, CTL, Treg, pDC, and neutrophil activity that predicts treatment‐free remission, while exhausted CTLs and Treg expansion predict relapse in chronic myeloid leukemia.
Hiroshi Ureshino, Shinya Kimura
wiley   +1 more source

Algorithm for Surgical Management in Patients in Treatment With Medication Associated With Osteonecrosis of the Jaws

open access: yesOral Surgery, EarlyView.
ABSTRACT Background Osteonecrosis of the jaws is associated with various drugs, including antiresorptives such as bisphosphonates and denosumab, as well as antiangiogenics. These drugs are used for the treatment of multiple diseases, notably osteoporosis, bone metastases, Paget's disease, osteogenesis imperfecta, malignant hypocalcaemia, among others ...
Rodríguez Naranjo Julia Alexandra   +3 more
wiley   +1 more source

Cancer‐associated fibroblast heterogeneity across solid and haematological malignancies: Lessons from colorectal cancer and multiple myeloma

open access: yesThe Journal of Physiology, EarlyView.
Abstract figure legend CAF origins and plasticity give rise to distinct phenotypes with immunosuppressive functions in colorectal cancer and multiple myeloma. These distinct CAF phenotypes contribute to immunosuppressive tumour microenvironments through ECM remodelling, cytokine signalling and immune regulation.
Hui Mo   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy